Abstract 228P
Background
Recent research has emphasized the pivotal role of tumor-associated macrophages (TAMs) in shaping the efficacy of anti-tumor therapies. Metabolic reprogramming is a key driver of TAM polarization, influencing their pro-tumorigenic or anti-tumorigenic phenotypes. However, the precise mechanisms by which tumor cells manipulate TAM metabolism remain elusive. We have currently discovered that agonistic anti-CD40 antibodies promote anti-tumorigenic TAM activation by enhancing mitochondrial activity and modulating fatty acid oxidation (FAO). We further investigated the interplay between mitochondrial fitness and FAO in regulating TAM immunosuppressive functions.
Methods
We conducted a series of in vitro and in vivo experiments using mouse melanoma tumor models and bone marrow-derived macrophages (BMDMs) for this study.
Results
Our findings demonstrate that lipid-accumulated TAMs exhibit impaired mitochondrial activity, exacerbating their pro-tumorigenic properties. Tumor-derived lipids influence mitochondrial dynamics in TAMs, leading to increased FAO, mitochondrial reactive oxygen species (mtROS) production, and mitophagy. These metabolic alterations collectively contribute to the pro-tumorigenic phenotype of TAMs. Moreover, our research suggests that targeting mitochondrial dynamics-associated pathways may represent a promising therapeutic strategy to reverse TAM immunosuppression and enhance anti-tumor immunity.
Conclusions
This study provides valuable insights into the intricate relationship between lipid metabolism, mitochondrial dynamics, and TAM polarization within the tumor microenvironment (TME). By elucidating how lipid metabolism interacts with mitochondrial dynamics to modulate TAM phenotypes, we aim to develop innovative therapeutic approaches targeting these pathways to improve anti-tumor responses.
Legal entity responsible for the study
The author.
Funding
National Science and Technology Council (MOST 111-2314-B-400-026-MY3).
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
165P - TIGIT inhibition in non-small cell lung cancer: Meta-analysis of clinical efficacy and biomarker correlation
Presenter: Hashim Talib Hashim
Session: Poster Display session
168TiP - A phase I dose escalation/expansion study of GSK5764227 (GSK’227), a B7-homolog 3 (B7-H3) protein targeted antibody-drug conjugate (ADC), in patients with advanced solid tumours
Presenter: Giuseppe Curigliano
Session: Poster Display session
169TiP - Colorectal carcinoma: Low dose immunotherapy in upfront metastatic d/MMR patients (CLOUD study)
Presenter: Anant Ramaswamy
Session: Poster Display session
177P - Ubiquitous neoantigens as targets for T cell recognition in a patient with metastatic pancreatic neuroendocrine tumour
Presenter: Jean-Benoit Tanis
Session: Poster Display session
178P - Comprehensive immunophenotype analysis in anti-PD-1 antibody sensitive and resistant syngeneic mouse model unravels perforin-expressing CD4+T cells dominant cytolytic activity
Presenter: Hiroyuki Inoue
Session: Poster Display session
179P - Impact of exercise training on tumour-infiltrating T cells in human prostate cancer
Presenter: Louise Lehrskov
Session: Poster Display session
180P - Chronic circadian disruption promotes melanoma progression by interfering with NK cells
Presenter: Shuwen Xiao
Session: Poster Display session
181P - Intratumoral heterogeneity of immune infiltrate in leiomyosarcomas
Presenter: Iva Benesova
Session: Poster Display session
182P - Innovative nano-immunotherapy for modulating tumor-immune interactions and microbiome in pancreatic cancer
Presenter: Liane Moura
Session: Poster Display session
183P - CAIX negatively modulates inflammatory and anti-tumor immune responses
Presenter: Eliska Svastova
Session: Poster Display session